From: Results from a Spanish national survey on the application of ultrasound in pulmonology services
SERVICES PORTFOLIO | Total N = 104 | High-complexity centre N = 58 | Intermediate-complexity centre N = 30 | Low-complexity centre N = 16 |
---|---|---|---|---|
LUS is routinely used to diagnose and manage PLEURAL EFFUSION | 95/104 (91.3%) | 55/58 (94.8%) | 27/30 (89.9%) | 13/16 (81.2%) |
LUS is routinely used to diagnose and/or follow-up INTERSTITIAL PULMONARY DISEASES | 16/104 (15.3%) | 10/58 (17.2%) | 1/30 (3.3%)b | 5/16 (31.2%) |
LUS is routinely used to rule out IATROGENIC PNEUMOTORAX after bronchopleural procedures | 53/104 (50.9%) | 36/58 (62.0%) | 10/30 (33.3%) | 7/16 (43.7%) |
LUS is routinely used for the diagnosis and/or follow-up of PNEUMONIA | 32/104 (30.7%) | 19/58 (32.7%) | 7/30 (23.3%) | 6/16 (37.5) |
LUS is routinely used to guide PULMONARY RECRUITMENT MANEUVERS | 6/104 (5.9%) | 5/58 (8.6%) | 0 (0%) | 1/16 (6.25%) |
LUS is routinely used to resolve DIFFERENTIAL DIAGNOSES between different pulmonary pathologies | 54/104 (51.9%) | 32/58 (55.1%) | 15/30 (49.9%) | 7/16 (43.7%) |
LUS is routinely used to assess VOCAL CORD DYSFUNCTION | 4/104 (3.8%) | 2/58 (3.4%) | 1/30 (3.3%) | 1/16 (6.25%) |
LUS is routinely used to diagnose and follow-up patients with COVID-19 | 29/104 (27.8%) | 18/58 (31.0%) | 6/30 (20%) | 5/16 (31.2%) |
ECOSCOPY is used for LVEF estimation, to measure cavities, for pericardial assessment, and to calculate the TAPSE | 25/104 (24.0%) | 15/58 (25.8%) | 6/30 (20%) | 4/16 (25%) |
LL ultrasound is routinely performed when thromboembolic disease is suspected | 28/104 (26.9%) | 12/58 (20.6%)a | 7/30 (23.3%)b | 9/16 (56.2%) |
ELASTOGRAPHY is used to assess masses | 8/104 (7.6%) | 7/58 (12.1%) | 0 (0%) | 1/16 (6.2%) |
ELASTOGRAPHY is used to assess pleural effusions | 6/104 (5.7%) | 4/58 (6.8%) | 1/30 (3.3%) | 1/16 (6.2%) |